References
- KeatingGMVildagliptin: a review of its use in type 2 diabetes mellitusDrugs201070162089211220964454
- AhrénBSchweizerADejagerSVildagliptin improves islet glucose sensing in patients with type 2 diabetesJ Clin Endocrinol Metab2009941236124319174497
- SchweizerADejagerSFoleyJEAssessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes populationDiabetes Obes Metab20101248549420518804
- Ligueros-SaylanMFoleyJESchweizerAAn assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trialsDiabetes Obes Metab20101249550920518805
- GerichJDPP-4 inhibitors: what may be the clinical differentiators?Diabetes Res Clin Pract20109013114020708812
- NeumillerJJWoodLCampbellRKDipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitusPharmacotherapy201030546348420411998
- BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab200810829018034842
- CoxDRThe continuity correctionBiochmetrika197057217219
- SweetingMJSuttonAJLambertPCWhat to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse dataStat Med2004231351137515116347
- AhrénBGomesRStandlETwelve and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care20041228742880